DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Bulletin > Acta Medica Nagasakiensia > Volume 64, No. 1 >

Rectourethral fistula during bevacizumab administration for cecum cancer after prostate brachytherapy: A case report.

File Description SizeFormat
ActMed64_35.pdf509.86 kBAdobe PDFView/Open

Title: Rectourethral fistula during bevacizumab administration for cecum cancer after prostate brachytherapy: A case report.
Authors: Inoue, Yusuke / Ito, Shinichiro / Torashima, Yasuhiro / Okada, Satomi / Kobayashi, Kazuma / Adachi, Tomohiko / Hidaka, Masaaki / Kanetaka, Kengo / Eguchi, Susumu
Issue Date: Jun-2020
Publisher: Nagasaki University School of Medicine / 長崎大学医学部
Citation: Acta medica Nagasakiensia, 64(1), pp.35-37; 2020
Abstract: Rectourethral fistula is rare complication after 125I low-dose-rate prostate brachytherapy, and gastrointestinal fistulas are widely recognized as a complication of bevacizumab. To our knowledge, this is the first case of rectourethral fistula during bevacizumab administration for cecum cancer after prostate brachytherapy. A 75-year-old man visited our hospital because of urinary retention and fecaluria. He had been receiving chemotherapy for one year against recurrence of cecum cancer. The chemotherapy regimens were bevacizumab and capecitabine plus oxaliplatin. He had undergone laparoscopic ileocecal resection for cecum cancer 1.5 years earlier. Eight months after the operation, recurrence was recognized. He had a history of prostate cancer and had received 125I low-dose-rate prostate brachytherapy for prostate cancer 17 years earlier. Computed tomography revealed air bubble from the rectum to the prostate and urethra. To prevent urinary tract infection, laparoscopic transverse colostomy and percutaneous cystostomy were performed. Although the patient's quality of life subsequently improved, the performance status declined remarkably. He was therefore transferred to another hospital and received the best supportive care. Rectourethral fistula is a rare but serious complication after 125I low-dose-rate prostate brachytherapy. The introduction of bevacizumab to patients who have received this therapy should be carefully considered.
Keywords: Rectourethral fistula / Bevacizumab / Prostate brachytherapy / Colon cancer
URI: http://hdl.handle.net/10069/40046
ISSN: 00016055
Type: Departmental Bulletin Paper
Text Version: publisher
Appears in Collections:Volume 64, No. 1

Citable URI : http://hdl.handle.net/10069/40046

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace